sterna biologicals is a biopharmaceutical company developing novel treatments for chronic inflammatory diseases such as asthma, COPD, atopic dermatitis, and ulcerative colitis. By adressing GATA-3, a master transcription factor that plays a pivotal role in regulating type-2 inflammation, the company's next generation antisense molecule hgd40, a DNAzyme, provides truly new and highly promising therapeutic options.